The incidence and mortality of cancer among autoimmune diseases (AID) was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.
All News
Heart Risks Elevated in RA Patients Despite Biologic Tx
Hopes that biologic drugs for rheumatoid arthritis (RA) would cancel the extra cardiovascular risks normally seen with the disease dimmed a little in the face of findings from a population-based study from Scandinavia.
Today, the U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals.
Dr. Jack Cush Reviews the news and journal reports from the past week in RheumNow.com.
A Nordic multinational collaborative study examined the risk of acute coronary syndrome (ACS) in rheumatoid arthritis and found a less than 2 fold increased risk of ACS patients initiating biologic disease-modifying antirheumatic drugs (bDMARDs) with little risk variation with short-ter
